SAN DIEGO, June 15, 2020 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the
appointment of Dr. Katharine Knobil
to the Company's Board of Directors. Dr. Knobil brings more than 20
years of leadership and expertise across a range of areas including
global clinical development, health outcomes and medical
affairs.
"Dr. Knobil has a wealth of pharmaceutical experience that spans
across all phases of research and clinical development. She has an
established record of growing and leading successful teams for
large organizations and a passion for delivering new potential
therapies to patients globally. We are confident that Kate's
expertise will be an invaluable asset as we continue to advance and
expand our robust pipeline," said Tina S.
Nova, Ph.D., Chairman of the Board of Directors of
Arena.
Dr. Knobil currently serves as Chief Medical Officer and Head of
Research and Development at Kaleido Biosciences. Prior to joining
Kaleido, she spent more than 20 years at GlaxoSmithKline (GSK) in
roles of increasing responsibility, most recently serving as Chief
Medical Officer. As CMO of GSK, she oversaw and aligned
medical affairs, health outcomes, global clinical safety and
medical governance across the pharmaceutical, vaccines, and
consumer businesses. Previously she served as CMO for
Pharmaceuticals at GSK from 2015 to 2017, and prior to that, was
senior vice president, Value Evidence and Outcomes. Dr. Knobil
first joined GSK in 1997 as a research physician in respiratory
clinical development, and subsequently held a number of roles,
including leading the European respiratory clinical team, and
building the late-stage clinical development for all therapeutic
areas in China. Dr. Knobil was
named one of 2018's Fiercest Women in Life Sciences by
FiercePharma. She has served on the Board of Directors of the
National Health Council and has been active with the National
Academies of Sciences, Engineering, Medicine, and the Patient
Centered Outcomes Research Institute. Dr. Knobil received her B.A.
from Cornell University, her M.D. from
University of Texas Southwestern
Medical School, and completed a Fellowship in Pulmonary and
Critical Care Medicine at the Johns Hopkins
Medical School.
About Arena Pharmaceuticals
ARENA
Pharmaceuticals is a team with a singular purpose – deliver
our important medicines to patients.
In a rapidly changing global market, we work with a sense of
urgency every day to understand the needs of all our stakeholders,
identify bold, sometimes disruptive, ideas to get our medicines to
patients, and relentlessly execute until it's done.
ARENA - Care More. Act Differently.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements
include, without limitation, statements about Dr. Knobil's expected
contributions, Arena's position, drive, portfolio, prioritization,
financial position, team, and building of the company. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Megan E. Knight
Arena Pharmaceuticals, Inc.
Director, Investor Relations
mknight@arenapharm.com
858.210.3635
Arena Media Contact:
IR@arenapharm.com
858.453.7200
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-appoints-biotech-executive-katharine-knobil-md-to-board-of-directors-301076715.html
SOURCE Arena Pharmaceuticals, Inc.